Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma
Clinical trial NCT03688451 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03688451
- Sponsor
- Tahir Latif
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-29
- Primary completion
- 2023-12-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.